{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000067","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.946366+00:00","generated_at":"2026-06-12T04:31:14.550615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Krystal Biotech reports Q2 2023 net loss $33.2M; VYJUVEK launch yields 121 patient start forms","bullets":["VYJUVEK approved May 19; 121 Patient Start Forms submitted in first six weeks of launch.","Cash, cash equivalents and investments $505.9M as of June 30, 2023.","Net loss $33.2M ($1.25 per share) vs $28.1M ($1.10 per share) in Q2 2022.","First CF patient dosed with KB407 in Phase 1 trial; KB707 IND accepted with Fast Track designation.","Positive coverage from UnitedHealthcare and other national/regional health plans for VYJUVEK."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000067","json":"https://secwatch.observer/filing/0001711279-23-000067.json","markdown":"https://secwatch.observer/filing/0001711279-23-000067.md","text":"https://secwatch.observer/filing/0001711279-23-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/0001711279-23-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/krys-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:31:14.550615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69f17c32fd1fcf9b16630770b7739618e070cf1a","claim":"Krystal Biotech, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/0001711279-23-000067-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}